Stem Cell Product Commercialization Focus of Summit

PHILADELPHIA, Jan. 7 /PRNewswire/ -- RRY Publications announced that the 4th Annual Stem Cell Summit, the premier gathering of stem cell company executives, scientists and investors, will focus on commercialization of stem cell therapies. The Summit is an intensive one-day event where attendees explore the therapeutic applications of adult and embryonic stem cells, the successful path to stem cell product commercialization, and the latest investment opportunities in this space.

The 4th Annual Stem Cell Summit features 35 corporate presenters, keynote speaker Dr. Arnold Caplan, Ph.D., and a scientific panel discussion. It will take place on February 17, 2009, at Bridgewaters in New York City's historic South Street Seaport.

Confirmed presenting stem cell companies include:

    3DM, Inc.                                 Incell Corporation, LLC
    Aastrom Biosciences, Inc.                 MaxCyte, Inc.
    Aldagen, Inc.                             Moraga Biotechnology Corporation
    AllCells, LLC                             Neuronyx, Inc.
    Arteriocyte, Inc.                         Novocell, Inc.
    ArunA Biomedical, Inc.                    NuVasive, Inc.
    BioE Corp.                                Osiris Therapeutics, Inc.
    California Stem Cell, Inc.                Progenitor Cell Therapy, Inc.
    Cellerix, S.A.                            SpineSmith, LP
    Cognate BioServices, Inc.                 Stemagen
    Cytori Therapeutics, Inc.                 Stematix, Inc.
    Gamida Cell Ltd.                          Stemina, Inc.
    Geron Corp.                               TiGenix NV
    Harvest Technologies Corp.                Tissue Genesis, Inc.
    Histogen, Inc.                            Vet-Stem, Inc.
    Histogenics Corporation

In addition to the company and product overviews, Robin R. Young, CFA, the leading medical technologies analyst in the United States with over 25 years of experience in the cardiovascular, orthopedic and biomaterials industries, will update his 10-year market forecast for the stem cell industry.

"2008 was a record-breaking year for stem cell technologies with three of the largest stem cell transactions ever recorded?one for more than $1 billion for distribution rights, another for $200 million from the U.S. government, and yet another for $85 million to purchase a single stem cell product line," said Young. "It is, therefore, possible that 2009 will be the year that stem cell companies and technologies cross the $100 million annual revenue line and become a billion-dollar-valuation industry."

4th Annual Stem Cell Summit Facts

    What:          2009's Premier Gathering of Stem Cell Company Executives,
                   Scientists and Investors
    When:          February 17, 2009
    Where:         Bridgewaters
                   11 Fulton Street
                   New York City
    Admission:     $1,200 advance registration (December 1, 2008 - January 31,
                   2009)
                   $1,500 (February 1 - 17, 2009)
    Information:   For presentation or sponsorship opportunities, contact Lisa
                   Carpenter at 877-817-6450 or lisa@ryortho.com. Additional
                   information, including registration details, is available
                   at www.stemcellsummit.com
           

    Contacts:       Lisa Carpenter
                    RRY Publications, LLC
                    877-817-6450
                    lisa@ryortho.com